Meet the Speakers

Brian Ogilvie, PhD

Dr. Brian Ogilvie is the VP of Scientific Consulting at BioIVT where he leads a team that advises clients on in vitro drug-drug interaction studies and program strategy. He received a Ph.D. in toxicology from the University of Kansas Medical Center. He has published various research articles and book chapters, and has been an invited speaker at numerous drug development conferences.

Ayman El-Kattan, PhD

Dr. Ayman F. El-Kattan is a seasoned pharmaceutical consultant with over 20 years of experience, specializing in preclinical drug ADCE-PK (Absorption, Distribution, Clearance, and Elimination Pharmacokinetics). His expertise spans various therapeutic areas, including inflammatory diseases, pain management, and neurological disorders. Dr. El-Kattan’s strategic leadership focuses on addressing ADME challenges, human dose projection, and drug-drug interactions, guiding successful drug development initiatives. He excels in optimizing physicochemical properties to refine ADCE challenges and identifying viable chemical leads for progression from drug discovery to preclinical stages. Dr. El-Kattan plays a crucial role in designing and interpreting nonclinical studies, leveraging advanced predictive modeling techniques to project human PK parameters and drug-drug interaction potential. He also provides scientific guidance, identifies biomarkers, and authors regulatory submissions.

Dr. El-Kattan began his career at Pfizer, contributing to the development of 8 Investigational New Drugs (INDs) and managing assets during various stages of clinical trials. At IFM Therapeutics, he helped identify clinical candidates later acquired by Novartis. He is also an adjunct professor at college of Pharmacy, URI.

Dr. El-Kattan is an active member of the American Association of Pharmaceutical Scientists (AAPS) and serve on the committee of the Drug Transporter community. Dr. El-Kattan is a prolific author with  over 90 published papers in peer-reviewed journals and book chapters and more than 100 presentations boasting an h-index of 38 and more than 4500 citations. He also authored a book titled "Oral Bioavailability Assessment: Basics and Strategies for Drug Discovery and Development" published by Wile

Mark Warren, PhD

Dr. Mark S. Warren is Senior Director of Transporter Services at BioIVT and has more than 25 years’ experience in the drug transporter field.  He has been a contract research services study director since 2010, initially at Optivia Biotechnology, and then at BioIVT, when BioIVT acquired Optivia in 2018. In this role he has worked with clients to design and complete more than a thousand transporter studies for IND filings.  Additionally, he collaborates with clients to determine how ADME and PK properties of investigational drugs are influenced by transporter mechanisms and optimizing those properties using SAR studies.   

Previously, Mark worked at XenoPort, Inc., where his work on improving drug PK properties by modifying chemical structures to take advantage of active transport mechanisms led to several clinical candidates, including the FDA-approved gabapentin enacarbil.  Mark also worked at Microcide Pharmaceuticals developing inhibitors of bacterial efflux transporters.  Mark received his B.S. in Genetics from UC Davis, his M.S. in Chemistry and Ph.D. in Chemistry and Biochemistry from UC San Diego, and he completed postdoctoral work on enzyme reaction mechanisms at the Pennsylvania State University.

Bhagwat Prasad, PhD

Dr. Bhagwat Prasad is a Professor of Pharmaceutical Sciences at the College of Pharmacy and Pharmaceutical Sciences, WSU, Spokane, WA. He leads several federally and industry-funded research programs focused on characterizing interindividual variability of drug transport and metabolism, utilizing quantitative proteomics and metabolomics. Dr. Prasad serves as the director of Proteomics-based Research in Non-Cytochrome P450 Enzymes (PRINCE), a consortium funded by pharma. Prior to WSU, Dr. Prasad held the position of Assistant Professor at the University of Washington (UW). Dr. Prasad has contributed published >135 peer-reviewed articles and delivered over 115 invited talks.

Tina Meuller, PhD

Dr. Tina Mueller is a Scientific Advisor for ADME-Tox Services at BioIVT. She joined BioIVT in 2023 and consults with customers and internal teams on in vitro ADME programs with a focus on in vitro DDI studies and compliance with regulatory guidelines. Tina obtained her PhD in Biochemistry and Microbiology and earned a Master’s in Environmental Sciences from the Swiss Federal Institute of Technology in Zurich, Switzerland. Before joining BioIVT, she was an Associate Director, Research at Cybin, a small biotech company developing new mental health therapeutics based on psychedelics, where she led the company’s research programs from early through late discovery. Additionally, Dr. Mueller served as a Research Associate Professor at Michigan State University, Senior Staff Scientist at Scripps Florida, and Professor for Biomedical Sciences at Keiser University.